[HTML][HTML] Cervical cancer benefits from trabectedin combination with the β-blocker propranolol: in vitro and ex vivo evaluations in patient-derived organoids
R Di Fonte, S Strippoli, M Garofoli, G Cormio… - Frontiers in Cell and …, 2023 - frontiersin.org
Background: Cervical cancer (CC) is characterized by genomic alterations in DNA repair
genes, which could favor treatment with agents causing DNA double-strand breaks (DSBs) …
genes, which could favor treatment with agents causing DNA double-strand breaks (DSBs) …
Cervical cancer benefits from trabectedin combination with the β-blocker propranolol: in vitro and ex vivo evaluations in patient-derived organoids
R Di Fonte, S Strippoli, M Garofoli… - Frontiers in cell …, 2023 - pubmed.ncbi.nlm.nih.gov
Background: Cervical cancer (CC) is characterized by genomic alterations in DNA repair
genes, which could favor treatment with agents causing DNA double-strand breaks (DSBs) …
genes, which could favor treatment with agents causing DNA double-strand breaks (DSBs) …
[HTML][HTML] Cervical cancer benefits from trabectedin combination with the β-blocker propranolol: in vitro and ex vivo evaluations in patient-derived organoids
R Di Fonte, S Strippoli, M Garofoli… - Frontiers in Cell and …, 2023 - ncbi.nlm.nih.gov
Background: Cervical cancer (CC) is characterized by genomic alterations in DNA repair
genes, which could favor treatment with agents causing DNA double-strand breaks (DSBs) …
genes, which could favor treatment with agents causing DNA double-strand breaks (DSBs) …
[PDF][PDF] Cervical cancer benefits from trabectedin combination with the β-blocker propranolol: in vitro and ex vivo evaluations in patient-derived organoids
R Di Fonte, S Strippoli, M Garofoli, G Cormio, S Serratì… - 2023 - researchgate.net
Background: Cervical cancer (CC) is characterized by genomic alterations in DNA repair
genes, which could favor treatment with agents causing DNA double-strand breaks (DSBs) …
genes, which could favor treatment with agents causing DNA double-strand breaks (DSBs) …
[引用][C] Cervical cancer benefits from trabectedin combination with the β-blocker propranolol: in vitro and ex vivo evaluations in patient-derived organoids
R Di Fonte, S Strippoli, M Garofoli, G Cormio, S Serratì… - 2023 - europepmc.org
Background: Cervical cancer (CC) is characterized by genomic alterations in DNA repair
genes, which could favor treatment with agents causing DNA double-strand breaks (DSBs) …
genes, which could favor treatment with agents causing DNA double-strand breaks (DSBs) …